The relationship between the new drug Dabotan and pemetinib/pemetinib for cholangiocarcinoma

The new cholangiocarcinoma drug Dabotan (Pemigatinib) and Pemigatinib are actually the same drug. Among them, dabotan is its trade name in the Chinese market, while pemetinib/pemetinib is the transliteration of its English name. This drug is a potent and selective oral inhibitor of FGFR subtypes 1/2/3, developed by Incyte. It is mainly used to treat adult patients with advanced, metastatic or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement.

Dabotan/pemetinib inhibits the phosphorylation ofFGFR1/2/3 and blocks the activity of the FGFR kinase domain binding to ATP, thereby blocking cell proliferation signals and inhibiting tumor growth. In clinical trials, the drug showed significant efficacy in patients with FGFR2 fusion/rearrangement of cholangiocarcinoma, with an objective response rate of 56.7% and a median progression-free survival of 9.6 months, which has obvious advantages over traditional chemotherapy. Although dabotan/pemetinib has shown good efficacy and safety in clinical trials, it has not yet been included in medical insurance and cannot be reimbursed by medical insurance. In addition, generic versions of the drug need to be carefully selected to avoid using illegal or unreliable quality products that may affect therapeutic efficacy and safety.

In general, dalbertan and pemetinib are different names for the same drug. It is a potent and selective oral inhibitor of FGFR isoforms 1/2/3. It is mainly used to treat adult patients with advanced, metastatic or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement. Its efficacy and safety have been initially verified in clinical trials, but relevant matters still need to be paid attention to when using it.